AstraZeneca PLC Filing of Form 20-F with SEC (9071G)
March 07 2018 - 2:01AM
UK Regulatory
TIDMAZN
RNS Number : 9071G
AstraZeneca PLC
07 March 2018
7 March 2018 07:00 GMT
FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND
EXCHANGE COMMISSION
AstraZeneca PLC (the Company) announced today that, on 6 March
2018, it filed its 2017 Annual Report on Form 20-F with the US
Securities and Exchange Commission (SEC). The document is available
for viewing on the SEC website at www.sec.gov and also on the
Company's website at www.astrazeneca.com. The Company will send any
holder of the Company's securities, upon request, a hard copy of
the Company's complete audited financial statements free of charge.
Requests may be made by writing to the Company Secretary,
AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical
Campus, Cambridge, CB2 0AA, UK.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology; Other +1 240 477 3771
Christer Gruvris Brilinta; Diabetes +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary
7 March 2018
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSIEFMFASELD
(END) Dow Jones Newswires
March 07, 2018 02:01 ET (07:01 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
